Exhibit 99.1

Calyxt Reports 1st Quarter Financial Results

Calyno High Oleic Soybean Oil is the first ever gene-edited food product to successfully undergo review by the USDA and FDA and be commercialized in the U.S.

Calyno High Oleic Soybean Oil is now available from one of the world’s largest broadline foodservice distributors

Sold out of seed and 3x acre growth, with 55,000 Calyxt soybean acres contracted for the 2019 growing season

Cash and cash equivalents of $85.7M at March 31, 2019

2019 seed deliveries began in second quarter, cash receipts of $1.8M expected over next 90 days

ROSEVILLE, Minn.--(BUSINESS WIRE)--May 7, 2019--Calyxt, Inc. (NASDAQ: CLXT), a healthy food ingredient company, today announced its results for the first quarter ended March 31, 2019.

Investor Call Details

Calyxt will host an investor call on May 8, 2019 at 8:30 a.m. Eastern Time – 7:30 a.m. Central Time to discuss its financial results and provide a general business update.

US & Canada only: +1 (877) 407-9747
International: +1 (412) 902-0044

In addition, a replay of the call will be available for one month following the conference by calling +1 (877) 660-6853 (Toll Free US & Canada); +1 (201) 612-7415 (Toll Free International).

The archived webcast of this event may be accessed through the Calyxt website, using passcode 13673206.


“In the first quarter of 2019, we achieved a monumental milestone for Calyxt with the successful commercial launch of Calyno oil. We are thrilled to see our High Oleic Soybean Oil either met or exceeded the performance and quality standards of the commercially available oils for qualities including fry life, trans-fat content, saturated fat content and flavor transfer. Following the initial commercial sale, we have identified and vetted a series of food customer opportunities and we are excited to announce that as of late April Calyno oil is available from one of the world’s largest broadline foodservice distributors” said Jim Blome, CEO of Calyxt. “On the farmer side, we are sold out of seed for the 2019 growing season and have tripled our acres from 2018 – we have partnered with over 150 selected growers who have contracted over 55,000 Calyxt soybean acres.”

Regulatory

As previously announced, Calyxt completed a consultation with the Food and Drug Administration (FDA) for its High Oleic Soybean. After review, FDA had no further questions concerning human food ingredients or animal food derived from our High Oleic Soybean. Calyno oil is the first gene-edited food product to undergo such review and be commercialized in the U.S.

High Oleic Soybean


Product Candidate Pipeline

Financial Highlights

Cash, cash equivalents and restricted cash were $85.7 million at March 31, 2019. We intend to continue to manage the use of cash and expect to have sufficient cash to fund the business into early 2021.

Our cash spend for 2019 is estimated at between $3 million and $3.5 million per month based on the increase in acreage contracted for the 2019 season and will be focused in these areas:

For the three months ended March 31, 2019, we incurred losses from operations of $7.4 million and used net cash in operating activities of $9.3 million.

For the three months ended March 31, 2018, we incurred losses from operations of $4.4 million and used net cash in operating activities of $6.6 million.

About Calyxt

Calyxt is committed to making the food you love a healthier choice. The care we take extends beyond nutritional value. We partner with farmers and food companies to deliver traceable plant-based products developed to be healthier and more sustainable than their conventional counterparts. We use cutting edge plant breeding techniques to develop products that help improve diets by reducing bad fats, allergens and toxins. Today oil from our high oleic soybean plants has lower saturated fats than commodity soybean oil. We are also developing high fiber wheat designed to provide an excellent source of daily fiber when incorporated into wheat-based foods. We continuously pursue innovation to deliver good food that is good for you.


Calyxt is located in Roseville, MN, and is listed on the Nasdaq market (ticker: CLXT). For further information please visit our website at www.calyxt.com.

Calyxt™, Calyno™ and the corporate logo are trademarks owned by Calyxt, Inc.

Calyxt Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, our anticipated growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including those factors discussed under the caption entitled “Risk Factors” in our Annual Report on Form 10-K, along with our other filings with the U.S. Securities and Exchange Commission. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by applicable laws.


CALYXT, INC.

BALANCE SHEETS

(In Thousands, Except Par Value and Share Amounts)

   
    March 31,

2019

(unaudited)

  December 31,

2018

Assets
Current assets:
Cash and cash equivalents

$

84,231

$

93,794

Restricted cash 381 381
Trade accounts receivable 124

-

Due from related parties 130 46
Inventory 379

-

Prepaid expenses and other current assets     1,778     1,301
Total current assets 87,023 95,522
Non-current restricted cash 1,120 1,113
Land, buildings, and equipment 21,854 21,850
Other non-current assets     674     306
Total assets   $ 110,671   $ 118,791

Liabilities and stockholders’ equity

Current liabilities:
Accounts payable $ 724 $ 818
Accrued expenses 1,610 2,007
Accrued compensation and benefits 887 1,305
Due to related parties 875 1,905
Current portion of financing lease obligations 264 258
Other current liabilities     290     711
Total current liabilities 4,650 7,004
Financing lease obligations 18,162 18,227
Other non-current liabilities     156     163
Total liabilities     22,968     25,394
Stockholders’ equity:

Common stock, $0.0001 par value; 275,000,000 shares authorized;
32,707,725 shares issued and 32,692,189 shares outstanding as of
March 31, 2019 and 32,664,429 shares issued and 32,648,893 shares
outstanding as of December 31, 2018

3 3
Additional paid-in capital 177,750 176,069
Common stock in treasury, at cost; 15,536 shares (230) (230)
Accumulated deficit     (89,820)     (82,445)
Total stockholders’ equity     87,703     93,397
Total liabilities and stockholders’ equity   $ 110,671   $ 118,791

CALYXT, INC.

STATEMENTS OF OPERATIONS

(Unaudited and in Thousands Except Shares and Per Share Amounts)

 
Three months ended March 31,
      2019   2018
Revenue

$

157

$ 11
Operating expenses:
Cost of revenue 34 -
Research and development 2,044 1,048
Selling, general and administrative 5,241 2,676
Management Fees     361   583
Total operating expenses     7,680   4,307
Loss from operations (7,523) (4,296)
Interest, net 172 (68)
Foreign currency transaction (loss) gain     (24)   (6)
Loss before income taxes (7,375) (4,370)
Income taxes     -   -
Net loss   $ (7,375) $ (4,370)
Basic and diluted loss per share   $ (0.23) $ (0.16)
Weighted average shares outstanding - basic and diluted     32,677,944   27,851,162

CALYXT, INC.

STATEMENTS OF CASH FLOWS

(Unaudited and in Thousands)

 
Three months ended March 31,
      2019   2018
Operating activities

Net loss

$

(7,375)

$

(4,370)

Adjustments to reconcile net loss to net cash used in operating
activities:

Depreciation 342 156
Stock-based compensation 1,556 40
Unrealized foreign exchange gain - 8
Changes in operating assets and liabilities:
Trade accounts receivable (124) -
Due to/from related parties (1,114) (496)
Inventory (379) -
Prepaid expenses and other assets (624) (880)
Accounts payable (94) (310)
Accrued expenses (397) 182
Accrued compensation and benefits (418) (456)
Other accrued liabilities     (708)   (439)
Net cash used by operating activities     (9,335)   (6,565)
Investing activities
Purchases of land, buildings and equipment     (346)   (41)
Net cash used by investing activities     (346)   (41)
Financing activities
Deferred offering costs - (69)
Proceeds from the exercise of stock options     125   714
Net cash provided by financing activities     125   645
Net decrease in cash, cash equivalents and restricted cash (9,556) (5,961)
Cash, cash equivalents and restricted cash - beginning of period     95,288   56,664
Cash, cash equivalents and restricted cash - end of period   $ 85,732 $ 50,703

CONTACT:
Media:
Jennifer Moore, VP Communications
Phone: +1 (917) 580-1088
email: media@calyxt.com

Investor Relations:
Simon Harnest, VP Corporate Strategy and Finance
Phone: +1 (646) 385-9008
email: simon.harnest@calyxt.com